Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Dr. Lal PathLabs Ltd - 539524 - Board Meeting Outcome for Outcome Of Board Meeting Held On February 02, 2023

 Please take note that the Board of Directors in their meeting held today i.e. February 02, 2023 approved the following item(s): 1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine months ended December 31, 2022. A copy of the above Financial Results along with Limited Review Reports thereon issued by the Statutory Auditors, M/s Deloitte Haskins & Sells, LLP for the Quarter and Nine months ended December 31, 2022 are attached herewith as an Annexure- A. 2. Appointment of Mr. Arun Duggal (DIN: 00024262) as an Additional Director in the category of Independent Director of the Company for a term of three (3) years commencing from February 02, 2023 subject to approval of Shareholders of the Company through postal ballot process.
02-02-2023
Bigul

Dr. Lal PathLabs Ltd - 539524 - Un-Audited Financial Results For Quarter And Nine Months Ended December 31, 2022

 Please take note that the Board of Directors in their meeting held today i.e. February 02, 2023 approved the following item(s): 1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine months ended December 31, 2022. A copy of the above Financial Results along with Limited Review Reports thereon issued by the Statutory Auditors, M/s Deloitte Haskins & Sells, LLP for the Quarter and Nine months ended December 31, 2022 are attached herewith as an Annexure- A. 2. Appointment of Mr. Arun Duggal (DIN: 00024262) as an Additional Director in the category of Independent Director of the Company for a term of three (3) years commencing from February 02, 2023 subject to approval of Shareholders of the Company through postal ballot process. The Board Meeting commenced at 11:00 A.M and concluded at 02:00 P.M.
02-02-2023
Bigul

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Acquisition

 Please take note that the Board of Directors of PathLabs Unifiers Private Limited ('PUPL') (a Wholly Owned Subsidiary of the Company) in their meeting on January 30, 2023 approved the acquisition of further 10% equity stake in its Subsidiary Company i.e. APRL PathLabs Private Limited ('APRL').
30-01-2023
Bigul

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the invite of the Conference Call for Investors/Analysts to be held on Thursday, February 02, 2023 at 05:00 pm IST to discuss the financial and operating performance for Q3 & 9M FY23.
27-01-2023
Bigul

Dr. Lal PathLabs Ltd - 539524 - Board Meeting Intimation for Notice Of Board Meeting

 Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2023 ,inter alia, to consider and approve the Un-Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Nine Months ended December 31, 2022.
24-01-2023
Bigul

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Credit Rating

 Please find attached the final copy of rating letter and press release, received today, from CARE Ratings Limited ('CARE') for the bank facilities of the Company.
10-01-2023

Lal PathLabs targets leadership position in west India in 5 years

 Om Manchanda, MD, Dr Lal Pathlabs said that the contribution of the west zone has gone up from 6 percent in FY15 to 8 percent in FY20 and 15 percent in the first half of FY23
08-01-2023
Bigul

Dr. Lal PathLabs Ltd - 539524 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Please find enclosed herewith a copy of the Certificate received from Link Intime India Private Limited, the RTA (Registrars & Share Transfer Agent) of the Company viz. Dr. Lal PathLabs Limited, confirming the compliance under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2022.
06-01-2023
Bigul

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

 We wish to inform you that, the Board of Directors have on January 03, 2023 approved allotment of 2,000 Equity Shares under the ESOP 2010 Plan of the Company.
03-01-2023
Bigul

F&O Query: Should I hold Dr Lal Path Labs futures or sell it?

 For the stock to turn bullish, it should surpass the 2,400-levels
02-01-2023
Next Page
Close

Let's Open Free Demat Account